First Republic Investment Management Inc. Acquires Shares of 5,605 Prometheus Biosciences, Inc. (NASDAQ:RXDX)
First Republic Investment Management Inc. Acquires Shares of 5,605 Prometheus Biosciences, Inc. (NASDAQ:RXDX)
First Republic Investment Management Inc. acquired a new stake in Prometheus Biosciences, Inc. (NASDAQ:RXDX – Get Rating) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,605 shares of the biopharmaceutical company's stock, valued at approximately $331,000.
根據第一共和投資管理公司在第三季度收購了普羅米修斯生物科學公司(納斯達克:RXDX-GET評級)的新股份,該公司在最近提交給美國證券交易委員會的Form 13F文件中稱。該公司收購了這家生物製藥公司5,605股股票,價值約331,000美元。
A number of other hedge funds have also recently added to or reduced their stakes in RXDX. Swiss National Bank grew its stake in Prometheus Biosciences by 7.4% in the first quarter. Swiss National Bank now owns 27,600 shares of the biopharmaceutical company's stock valued at $1,042,000 after acquiring an additional 1,900 shares during the period. JPMorgan Chase & Co. grew its stake in Prometheus Biosciences by 454.6% in the first quarter. JPMorgan Chase & Co. now owns 82,927 shares of the biopharmaceutical company's stock valued at $3,131,000 after acquiring an additional 67,975 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Prometheus Biosciences by 10.1% during the first quarter. Bank of New York Mellon Corp now owns 128,626 shares of the biopharmaceutical company's stock valued at $4,857,000 after buying an additional 11,844 shares during the last quarter. MetLife Investment Management LLC boosted its position in shares of Prometheus Biosciences by 55.4% during the first quarter. MetLife Investment Management LLC now owns 17,464 shares of the biopharmaceutical company's stock valued at $659,000 after buying an additional 6,227 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Prometheus Biosciences by 3.4% during the first quarter. Rhumbline Advisers now owns 37,177 shares of the biopharmaceutical company's stock valued at $1,404,000 after buying an additional 1,226 shares during the last quarter. Institutional investors and hedge funds own 78.31% of the company's stock.
其他一些對衝基金最近也增持或減持了RXDX的股份。瑞士國家銀行第一季度在普羅米修斯生物科學公司的持股增加了7.4%。瑞士國家銀行目前持有這家生物製藥公司27,600股股票,價值1,042,000美元,在此期間又購買了1,900股。摩根大通第一季度在普羅米修斯生物科學公司的持股增加了454.6%。摩根大通在此期間增持了67,975股,目前持有這家生物製藥公司82,927股股票,價值3,131,000美元。紐約梅隆銀行(Bank Of New York Mellon Corp)第一季度將其在普羅米修斯生物科學公司(Prometheus Biosciences)的股票頭寸增加了10.1%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有這家生物製藥公司128,626股股票,價值4,857,000美元,此前該公司在上個季度又購買了11,844股。大都會人壽投資管理公司在第一季度將其在普羅米修斯生物科學公司股票的頭寸增加了55.4%。大都會人壽投資管理有限責任公司現在擁有這家生物製藥公司17,464股股票,價值65.9萬美元,在上個季度又購買了6,227股。最後,Rhumbline Advisers在第一季度將其在普羅米修斯生物科學公司的股票頭寸增加了3.4%。Rhumbline Advisers現在擁有這家生物製藥公司37,177股股票,價值1,404,000美元,上個季度又購買了1,226股。機構投資者和對衝基金持有該公司78.31%的股票。
Prometheus Biosciences Stock Performance
普羅米修斯生物科學公司股票表現
Shares of RXDX opened at $106.02 on Thursday. The firm has a market cap of $4.45 billion, a PE ratio of -31.65 and a beta of -0.52. The stock's fifty day moving average price is $105.41 and its two-hundred day moving average price is $69.42. The company has a debt-to-equity ratio of 0.11, a current ratio of 11.19 and a quick ratio of 11.19. Prometheus Biosciences, Inc. has a 1 year low of $21.50 and a 1 year high of $122.75.
週四,RXDX的股價開盤報106.02美元。該公司市值為44.5億美元,市盈率為-31.65,貝塔係數為-0.52。該股的50日移動均線價格為105.41美元,200日移動均線價格為69.42美元。該公司的債務權益比為0.11,流動比率為11.19,速動比率為11.19。普羅米修斯生物科學公司的一年低點為21.5美元,一年高位為122.75美元。
Insider Buying and Selling at Prometheus Biosciences
普羅米修斯生物科學公司的內幕買賣
In other Prometheus Biosciences news, CFO Keith W. Marshall sold 5,000 shares of the business's stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $119.00, for a total value of $595,000.00. Following the sale, the chief financial officer now directly owns 9,811 shares in the company, valued at $1,167,509. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CFO Keith W. Marshall sold 5,000 shares of the business's stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $119.00, for a total transaction of $595,000.00. Following the sale, the chief financial officer now directly owns 9,811 shares in the company, valued at approximately $1,167,509. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Mark C. Mckenna sold 25,000 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $118.99, for a total value of $2,974,750.00. Following the sale, the chief executive officer now owns 55,144 shares in the company, valued at $6,561,584.56. The disclosure for this sale can be found here. Corporate insiders own 3.40% of the company's stock.
在普羅米修斯生物科學公司的其他消息中,首席財務官基思·W·馬歇爾在1月17日星期二的一次交易中出售了5000股普羅米修斯生物科學公司的股票。這隻股票的平均售價為119.00美元,總價值為595,000.00美元。出售後,這位首席財務官現在直接持有該公司9811股,價值1167,509美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過這個環節。在相關新聞中,首席財務官基思·W·馬歇爾在1月17日星期二的一次交易中出售了5000股該公司的股票。該股以119.00美元的平均價格出售,總成交金額為595,000.00美元。出售後,首席財務官現在直接擁有該公司9811股,價值約1167,509美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站。此外,首席執行官馬克·C·麥肯納在1月17日星期二的一次交易中出售了2.5萬股該公司的股票。這些股票的平均價格為118.99美元,總價值為2974,750.00美元。出售後,這位首席執行官現在擁有該公司55,144股,價值6,561,584.56美元。關於這次銷售的披露可以找到這裏。企業內部人士持有該公司3.40%的股份。
Analyst Ratings Changes
分析師評級發生變化
RXDX has been the topic of several analyst reports. The Goldman Sachs Group lifted their target price on Prometheus Biosciences from $117.00 to $144.00 and gave the company a "buy" rating in a research report on Tuesday, January 31st. Stifel Nicolaus lifted their target price on Prometheus Biosciences from $50.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, November 1st. Royal Bank of Canada lifted their target price on Prometheus Biosciences from $66.00 to $111.00 in a research report on Wednesday, December 7th. BTIG Research lifted their price target on Prometheus Biosciences from $74.00 to $181.00 and gave the stock a "buy" rating in a report on Thursday, December 8th. Finally, Piper Sandler lifted their price target on Prometheus Biosciences from $67.00 to $114.00 in a report on Wednesday, December 7th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Prometheus Biosciences currently has a consensus rating of "Buy" and a consensus price target of $117.10.
RXDX一直是幾份分析師報告的主題。高盛夫婦將他們對普羅米修斯生物科學公司的目標價從117.00美元上調至144.00美元,並在1月31日週二的一份研究報告中給出了該公司“買入”的評級。Stifel Nicolaus在11月1日週二的一份研究報告中將其對普羅米修斯生物科學公司的目標價從50.00美元上調至55.00美元,並給予該公司“買入”評級。12月7日,加拿大皇家銀行在一份研究報告中將他們對普羅米修斯生物科學公司的目標價從66美元上調至111.00美元。BTIG Research將他們對普羅米修斯生物科學公司的目標價從74美元上調至181.00美元,並在12月8日星期四的一份報告中給予該股“買入”評級。最後,派珀·桑德勒在12月7日星期三的一份報告中將他們對普羅米修斯生物科學公司的目標價從67美元上調至114.00美元。根據MarketBeat的數據,九位分析師對該股的評級為買入,普羅米修斯生物科學公司目前的共識評級為買入,共識目標價為117.10美元。
Prometheus Biosciences Company Profile
普羅米修斯生物科學公司簡介
(Get Rating)
(獲取評級)
Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease.
普羅米修斯生物科學公司是一家生物製藥公司,致力於治療炎症性腸病(IBD)的新型療法和伴隨診斷產品的發現、開發和商業化。它的主要產品包括PRA023,一種人源化的IgG1單抗(MAb),正處於IIa期臨牀試驗,用於治療潰瘍性結腸炎和克羅恩病,以及系統性硬化症相關的間質性肺疾病。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Prometheus Biosciences (RXDX)
- CVS Health Corporation Is Coiled And Ready To Spring Higher
- Will The Pullback In Paycom Payoff For Investors?
- TJX Among Apparel Retailers All Dressed Up & Ready For Growth
- Daqo New Energy Charged Up For New Highs
- No Spice In Chipotle Results, Is Now The Time To Buy?
- 免費獲取StockNews.com關於普羅米修斯生物科學的研究報告(RXDX)
- CVS Health Corporation捲土重來,準備跳得更高
- Paycom的回調會給投資者帶來回報嗎?
- 服裝零售商中的TJX都盛裝打扮,為增長做好了準備
- 大全新能源再創新高
- Chipotle結果中沒有香料,現在是買入的時候了嗎?
Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《普羅米修斯生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對普羅米修斯生物科學公司和相關公司的最新新聞和分析師評級的每日簡要摘要。